Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma

NCT00180011 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

18

Enrollment

INDIV

Sponsor class

Conditions

Asthma

Interventions

DRUG: Omalizumab

Sponsor

DiMango, Emily, M.D.

Collaborators

[object Object]
[object Object]